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There are a number of polyglanduler disorders
characterized by autonomous hyperfunction of more than
one endocrine gland. The majority of these disorders are
of genetic origin. In this context there are three
syndromes worth of mentioning:
1. Multiple Endocrine Neoplasia, Type 1(MEN1; or
Wermer’s Syndrome) where there are multiple tumors of
the anterior pituitary, parathyroid glands, and pancreatic
island cells(especially insulinoma and gastrinoma).
2.Multiple Endocrine Neoplasia, Type 2a (MEN2a; or
Sipple’s Syndrome) which is an entirely different
syndrome characterized by medullary carcinoma of the
thyroid,
pheochromocytoma,
and
parathyroid
hyperplasia.
3. Multiple Endocrine Neoplasia, Type 2b (MEN 2b;
Mucosal Neuroma Syndrome) which resembles MEN2a
but consists of additional clinical features such as
disfiguring neuromas of the lips, tongue,
ganglioneuromas of the gastrointestinal tract and a
marfanoid body habitus (1).
Although the clinical features of these syndromes are
well defined, the mechanism of the pathophysological
process (from the gene to the clinical symptoms) still
remains a mystery.
Herein we describe a patient whose initial clinical
presentation was intractable peptic ulcer disease but
during the follow up turned out to be a case of
insulinoma in addition to gastrinoma.The patient, a 35
year old policeman, was admitted to our hospital because
of episodic confusion and recurrent syncope. He had been
well until 1986 when he developed peptic ulcer disease
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which was refractory to medical therapy. He underwent
gastric surgery twice in 1986 and 1988 without relief.
Shortly afterwards the second operation he developed
weight loss and persistent diarrhea which was thought to
be due to dumping syndrome. Meanwhile he began to
have episodic dizziness and confusion. Plasma glucose
concentrations determined at the time of symptoms
varied between 45-65 mg/100ml.
The physical examination revealed a
(approximately 5x5cm) in the left hypocondrium.

mass

Laboratory studies revealed mild normocytic
normochromic anemia (Hct%36.7, MCV 82.6 µ3), and
hypoglycemia (45 mg/dL). Other parameters of total
blood count and blood chemistry (BUN, creatinin, uric
acid, sodium, potassium, chloride, calcium, phosphorus,
alkaline phosphatase, SGOT, SGPT, LDH, CPK, total and
direct bilirubin, cholesterol, triglyceride, total protein and
albumin) were normal. Blood glucose concentration
determinations performed on several occasions (when the
patient displayed symptoms such as syncope, confusion)
varied between 29-45 mg/dL, necessitating a continuous
perfusion of %20 glucose solution. Blood insulin and C
peptide levels measured during a hypoglycemic attack
(blood glucose level was 30 mg/dL) were %74 µiu/ml
(normal values:0-30) and 4.2 ng/ml (normal values:0.84) respectively, supporting a diagnosis of insulinoma. The
gastrin level was 2600 pg/ml (Normal:<90 pg/ml). An
abdominal ultrasonography revealed a hypoechogenic
area (73x37 mm) in the corpus and tail of the pancreas
as well as multiple hypoechogenic nodules in the liver
(Figures 1 and 2). A computed tomographic scan also
showed multiple masses in the liver in addition to a mass
451
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Figure 1.

Abdominal ultrasonography revealed a hypoechogenic area
in the tail and corpus of the pancreas.

filling the left upper quadrant of the abdominal cavity
which obscured the corpus and tail of the pancreas
(Figure 3). A gastroscopic examination showed diffuse
thickening of the mucosa in the corpus and petechial
bleeding, which raised a suspicion of granulomatous
gastritis or lymphoma. However, the pathologic
examination of the biopsy specimens revealed chronic
gastritis and metaplasyc changes of pyloric type.
Our original clinical impression was that the patient
was a case of Zollinger-Ellison Syndrome because all the
clinical and laboratory findings (intractable peptic ulcer
disease necessitating gastric surgery twice; persistent
diarrhea and hypergastrinemia) implied the presence of a
gastrinoma. The other clinical features such as dizziness
and recurrent confusional episodes were thought to be
due to postprandial hypoglycemia, a component of
dumping syndrome. However, low fasting blood glucose
concentrations accompanying increased levels of insulin
and C-peptide excluded this possibility and lead to a
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Figure 2.

Abdominal ultrsonography shows multiple metastatic
nodules in the liver.

diagnosis of insulinoma in addition to gastrinoma. We
performed further laboratory studies in regard of other
autonomous functioning endocrine tumors, which were
all negative: Scintigraphic examination of the parathyroid
glands, plasma concentrations of parathormon, thyroid
hormones T3 and T4, TSH, LH, PRL, FSH, and 24 hour
urinary excretion of vanil mandylic acid and 5-OH indol
acetic acid. Computed tomographic scanning of the
pituatary gland was normal. The patient was considered
ineligible for curative surgery and a biopsy specimen
obtained from the liver under computerized axial
tomographic assistance revealed non-specific changes in
the liver, while examination of another specimen obtained
at the same session from the mass behind the stomach
showed tumoral cells originating from the islet cells of
the pancreas (islet cell type small cell tumor). These cells
had a weak affinity for gastrin stain but were painted well
with gramelius stain (Figure 4).
Since the hypoglycemic attacks were unresponsive to
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Figure 3.

Abdominal
computed
tomography. Multiple masses in
the liver and another mass filling
the left upper quadrant of the
abdominal cavity and obscuring
the corpus and tail of the
pancreas. There is also splenic
hiler invasion with posterior
displacement of the splenic vein.

after the beginning of a chemotherapeutic regimen
involving adriamycin and vepesid (in accordance with
oncologic consultation) the patient died of massive
gastrointestinal bleeding.

Figure 4: Histopathologic specimen. Islet cell type small tumoral cells
with weak affinity for gastrin stain but painting well with
gramelius stain.

20% glucose infusion, the patient was given octreotide
(2x100u sc.) after which the blood glucose concentration
increased while the C-peptide level decreased. Shortly

Insulinomas and gastrinomas are rare tumors and the
coexistence of them in the same patient is even rarer. In
clinical practice one can encounter them in sporadic form
or as a part of MEN1 syndrome. It is reported that %1520 of patients with Zollinger-Ellison Syndrome and %3 of
patients with insulinoma have other endocrine neoplasms
(2). On the other hand, islet cell tumors of the pancreas
are present in 65-80% of patients with MEN1 Syndrome.
These tumors are typically multifocal and secrete multiple
peptides either concurrently or at different times during
the course of the disease (3). Although it is difficult to
establish a diagnosis of MEN1 in the absence of other
endocrine tumors other than insulinoma and gastrinoma,
(especially adenomas of the parathyroid glands), it is
known that affected individuals may demonstrate
multiple endocrine involvement simultaneously or years
may elapse between the discovery of one tumor and the
next (4). Moreover, many gastrin and insulin secreting
islet cell tumors contain other hormones including ACTH,
glucagon, parathyroid hormone, etc., which are usually
clinically silent (5, 6), and it is also reported that solitary
sporadic tumors secreting multiple peptides may mimic
MEN1 syndrome (7). It is recommended that all patients
with pancreatic endocrine tumors, regardless of their
initial clinical picture should undergo continuous
monitoring for new elevations of hormones (8).
All these facts are compatible with the clinical
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progress of our case who developed symptomatic
hypoglycemia years after intractable peptic ulcer.
Although we did not detect laboratory findings of
hyperparathyroidism during the follow up, it remains as a
possibility, albeit weak, that our patient would have
developed hypercalcemia had he lived long enough. So,
we think that this patient should be regarded as a
potantiel case of MEN1 syndrome.
There are some interesting clinical observations which
can be explanied by the interactions of multiple hormones
produced by pancreatic tumors: In a patient streptozocin
therapy for metastatic gastrinoma unveiled the presence
of an insulinoma (9), and surgical removal of pancreatic
tumors secreting somatostatin in addition to insulin can
cause postoperative hypergastrinemia and gross peptic
ulceration (10).
It is reported that 50% of insulinomas and
gastrinomas are not evident on preoperative imaging
studies.
Calcium
angiography,
endoscopic
ultrasonography, isotope labeled octreotide scanning are
new promising imaging techniques. Intraoperative
angiography and ultrasound are considered as the best
methods for intraoperative detection of insulinomas. On
the other hand, for gastrinomas, intraoperative
endoscopic transullimination and duodenotomy are

important due to the fact that 30-40% of gastrinomas
are found in the duodenal wall (11).
The results of surgical intervention are different in the
two types of pancreatic tumors. Insulinomas are reported
to be resectable in over 90% of cases (12), and surgery
is indicated in patients with MEN1 syndrome even if a
lesion is not visualized radiologically (13). This is in
contrast to gastrinomas, where only 15-20% of tumors
are resectable, and those associated with MEN1
syndrome are considered ineligible for surgery due to
multifocal involvement (14). It is reported that surgical
removal of islet cell tumors did not cure hypergastrinemia
and Zollinger-Ellison syndrome in patients with MEN1
(13, 15, 16). Nevertheless, some advocate debulking
surgery whenever possible in hormone active pancreatic
tumors in regard of the success of subsequent medical
therapy (17).
The invention of histamine receptor blockers and
more recently proton-pump inhibitors have changed the
grave outlook of unresectable gastrinomas dramatically.
Octreotide, a long acting somatostatine analogue, is also
a potent drug in alleviating symptoms due to
hypergastrinemia. On the other hand, neither octreotide
nor diazoxide are effective in controlling hypoglycemia in
patients with insulinoma (18, 19). Fortunately, as
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